Connect Sign In
Two members of the ARUP Healthcare Advisory Services team have built the basis for an open access database that could change the way researchers perform meta-analyses.
Society's growing and changing understanding of how race, ethnicity, or ancestry (REA) is experienced and interpreted is prompting many clinical labs to reexamine practices related to REA data.
ARUP study finds pharmacogenetic testing to evaluate drug-gene interactions improves patient outcomes and patients' confidence in overall care.
Biomarker testing can aid in the accurate diagnosis and treatment of cancer, but integrating precision medicine into routine clinical care can be a challenge.
A lot has changed in laboratory medicine during the last 100 years. To celebrate Lab Week 2022, here are five resources that examine the past, present, and future of medical laboratory science.
ARUP’s next generation sequencing (NGS) tests are now faster and more precise thanks to the launch of Rio, a new world-class bioinformatics pipeline and analytics platform.
PacBio and ARUP Laboratories announced they are collaborating on a study intended to evaluate whether the solve rate for rare disease cases can be increased.
ARUP Consult released new and updated resources on genetic cardiovascular disease, the effects of common anticoagulants on coagulation testing, laboratory testing for primary sclerosing cholangitis.
Utah added screening for GAMT deficiency to its NBS panel in 2015, becoming the first state to do so. It is now one of only three states to screen for the condition.
In December 2020, Utah’s Newborn Screening Program identified the first patient with guanidinoacetate methyltransferase (GAMT) deficiency solely through newborn screening.
Karl Voelkerding, MD, FCAP, retired from his position as medical director of genomics and bioinformatics at ARUP on July 1, 2020. Karl Voelkerding, MD, FCAP, once imagined practicing medicine as a primary care physician in a rural setting. Instead, Voelkerding would become one the world’s leading experts in NGS.
ARUP Laboratories announced today that the Food and Drug Administration (FDA) has filed ARUP’s premarket approval application (PMA) for an AAV5 total antibody assay.
